Please assess the completion status of the following clinical trial:

Trial Title: A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A subject with a histologically or cytologically confirmed diagnosis of malignant solid tumor which is refractory to standard therapy or to which no effective standard therapy is applicable~* An archived tumor tissue is available or biopsy of tumor tissues can be newly performed~* A Japanese male or female, age greater than or equal to (\>=) 20 years~* A subject who has read the Subject Information Sheet and understood the details of this clinical trial, and is willing and able to give his/her informed consent.~* A female of child-bearing potential must have a negative blood pregnancy test result at her screening period. A female subject of child-bearing potential must be willing to avoid pregnancy by using an adequate method of contraception Life expectancy is at least 3 months~* Other inclusion criteria apply~Exclusion Criteria:~* Known Human immunodeficiency virus (HIV) positivity, active hepatitis C, or active hepatitis B~* Presence of liver fibrosis or liver cirrhosis that has been histologically diagnosed~* Signs or symptoms that suggest transmissible spongiform encephalopathy~* Received major surgery within 6 weeks before Day 1 in Cycle 1~* Known drug abuse or alcohol abuse~* Known hypersensitivity to any of the trial treatment ingredients~* Hematological test abnormalities~* Renal impairment as defined in the protocol~* Liver dysfunction as defined in the protocol~* History or presence of central nervous system metastasis~* History or presence of disease or condition that may hamper compliance or absorption of the investigational medicinal product (IMP) due to difficulty in swallowing or absorption~* Poor performance status of Eastern Cooperative Oncology Group Performance status (ECOG PS) \>= 2~* Received any anti-cancer therapy days Received extensive prior radiotherapy that irradiates more than 30 percent of bone marrow~* Received any radiotherapy within 4 weeks before Day 1 in Cycle 1~* Pregnancy and lactation period~* History of receiving treatment with any c-Met signaling pathway inhibitor~* Participation in another interventional clinical trial within the past 30 days from Day 1 in Cycle 1~* Other significant disease that in the Investigator's opinion would exclude the subject from the trial~* Legal incapacity or limited legal capacity~* Other exclusion criteria apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MSC2156119J (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).